Literature DB >> 869147

Treatment of porcine malignant hyperpyrexia. The successful use of dantrolene in the Pietrain pig.

G M Hall, J N Lucke, D Lister.   

Abstract

The effect of dantrolene on porcine malignant hyperthermia in the Pietrain pig was studied. Five out of six pigs were successfully treated with dantrolene and the alkaline solvent was found to have no therapeutic effect.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 869147     DOI： 10.1111/j.1365-2044.1977.tb09985.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN： 0003-2409            Impact factor:   6.955


  7 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

2.  Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

Authors:  B A Britt; E Scott; W Frodis; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1984-03

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

4.  Porcine malignant hyperthermia--failure of dantrolene dose response to diagnose susceptibility (halothane effect).

Authors:  E H Flewellen; T E Nelson; D E Bee
Journal:  Can Anaesth Soc J       Date:  1980-01

5.  The effect of dantrolene on skeletal-muscle sarcoplasmic-reticulum function in malignant hyperpyrexia in pigs.

Authors:  M D White; J G Collins; M A Denborough
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

6.  Does prior dantrolene affect the in vitro diagnosis of malignant hyperthermia susceptibility?

Authors:  T E Nelson; E H Flewellen
Journal:  Can Anaesth Soc J       Date:  1979-11

Review 7.  The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.

Authors:  Saadet Inan; Huafeng Wei
Journal:  Anesth Analg       Date:  2010-09-22       Impact factor: 6.627
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.